Wabtec Corp.: Citigroup cuts target price to $338 from $341
WAB•Citigroup cut its target price for Wabtec to $338 from $341.
Related News
AngioDynamics Q1 sales beat on med tech segment growth
ANGO•
Perspective Therapeutics says FDA grants Fast Track status for [212Pb]PSV359 in FAP-positive solitary fibrous tumors
CATX•
TSMC controller Chen Chih-Ho acquires $2,461 of common shares
TSM•
RBC raises Rhythm Pharmaceuticals target price to $159 from $155
RYTM•
Cytokinetics raises target price to $113 from $112
CYTK•